Trial · NCT07069569
A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs
NCT07069569, Phase 2, Recruiting, Ausper Biopharma Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs. Trials, record NCT07069569. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07069569
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs
- NCT number
- NCT07069569
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 200 participants, estimated
- Lead sponsor
- Ausper Biopharma Co., Ltd.
- Conditions
- Chronic Hepatitis B
- Interventions
- AHB-137, Peg-IFN, Hepatitis B Vaccine
- First posted
- 2025-07-16
- Last updated
- 2026-07-29
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of participants with persistent HBsAg < limit of detection (LOD) and HBV DNA < lower limit of quantification (LLOQ) at the 24th week after all treatment for CHB was discontinued. | up to 72 weeks | |
| Secondary | Proportion of participants with persistent HBsAg < LOD and HBV DNA < LLOQ . | Up to 72 weeks | |
| Secondary | Detection of the serum concentration of HBsAg, HBsAb, HBV DNA, HBV RNA, HBcrAg, HBeAb,and HBeAg. | Up to 72 weeks | |
| Secondary | Proportion of participants who met discontinuation criteria for NAs treatment at the end of the treatment period. | Up to 48 weeks | |
| Secondary | Relapse rate after discontinuation of NAs therapy. | Up to 72 weeks | |
| Secondary | Change from baseline in alanine aminotransferase (ALT) values and time to normalization of values. | Up to 72 weeks | |
| Secondary | Relapse time after discontinuation of NAs therapy. | Up to 72 weeks | |
| Secondary | Plasma concentrations of AHB-137. | Up to 48 weeks | |
| Secondary | Serum concentrations of Peg-IFN. | Up to 48 weeks. | |
| Secondary | Safety: Number and percentage of participants with detectable anti-drug antibodies (ADA). | Up to 72 weeks |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07069569
GET https://conductscience.org/api/trials/v1/NCT07069569/registered